BEBT-908 DLBCL Treatment: A Milestone Approval ...

By João L. Carapinha

July 8, 2025

The recently published article from BeBetter Med (China) highlights the conditional approval of BEBT-908 DLBCL treatment (ifupinostat hydrochloride, trade name: 贝特琳®/Bertlin) by China’s National Medical Products Administration (NMPA). This inno...
AI Clinician in Pediatric ICU: A Review and HEOR Perspective
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Efficacy of Ultomiris Pediatric TMA Treatment
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies
RFK Jr.’s ACIP Overhaul: Examining Vaccine Policy Implications